Louisiana State Employees Retirement System lowered its holdings in Bioverativ Inc (NASDAQ:BIVV) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,400 shares of the biotechnology company’s stock after selling 1,500 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Bioverativ were worth $1,477,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Advisors Asset Management Inc. bought a new stake in Bioverativ in the third quarter valued at about $137,000. TCI Wealth Advisors Inc. bought a new stake in Bioverativ in the third quarter valued at about $186,000. Ladenburg Thalmann Financial Services Inc. bought a new stake in Bioverativ in the third quarter valued at about $190,000. Canada Pension Plan Investment Board bought a new stake in Bioverativ in the third quarter valued at about $194,000. Finally, ACG Wealth bought a new stake in Bioverativ in the third quarter valued at about $205,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $64.11 on Friday. Bioverativ Inc has a 52 week low of $40.99 and a 52 week high of $65.09.
A number of analysts recently weighed in on BIVV shares. Morgan Stanley reissued an “underweight” rating and issued a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 target price on the stock in a research note on Thursday, October 19th. Piper Jaffray Companies reissued an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the company a “hold” rating in a research note on Monday, November 20th. Finally, Jefferies Group upped their price objective on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Bioverativ presently has a consensus rating of “Hold” and an average price target of $62.53.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3148640/louisiana-state-employees-retirement-system-has-1-48-million-position-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.